This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (27)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Treatment Adherence  • Adherence  • Alert me on articles by topic

Richard W. Grant, MD, MPH; Kathleen M. O’Leary, BA; Jeffrey B. Weilburg, MD; Daniel E. Singer, MD; James B. Meigs, MD, MPH

Arch Intern Med. 2004;164:2343-2348.

Background  Effective therapy for chronic illness requires daily medication adherence (DMA) for prolonged periods. Overall medical regimen complexity may represent one barrier to successful adherence.

Methods  To assess the relationship between the number of concurrently prescribed medicines and adherence to 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), we analyzed a cohort of 5488 patients in a single health insurance plan who began statin therapy between July 1, 1999, and June 30, 2002. We assessed 2 parameters of statin adherence: (1) DMA ([total number of pills dispensed/total number of days between first and last prescription]  x100) and (2) refill persistence (RP) (consecutive months of refills after initial prescription).

Results  The cohort was 61.6% male, with a mean ± SD age of 52.7 ± 9.3 years. Patients were prescribed a mean ± SD of 2.9 ± 2 total medicines (range, 1-13), with a mean ± SD statin DMA of 82.1% ± 26.5%. By 12 months, only 68% of patients continued filling statin prescriptions. After controlling for age, income level, and treatment for hypertension or ischemic heart disease, a greater number of concurrently prescribed medicines was significantly associated with better DMA (P = .005) and longer RP (P = .03).

Conclusions  In this cohort, statin DMA was generally adequate, but RP was suboptimal. Patients with more concurrently prescribed medicines had higher DMA and better RP, even after adjusting for demographic factors and cardiovascular comorbidity. Physicians should not be deterred from initiating statin therapy by a patient’s medical regimen complexity but should be alert for lack of therapy persistence, particularly in younger and healthier patients.

Author Affiliations: General Medicine Unit, Department of Medicine (Drs Grant and Meigs), Clinical Research Program (Drs Grant, Singer, and Meigs), and Department of Psychiatry (Ms O’Leary and Dr Weilburg), Massachusetts General Hospital, and Harvard Medical School (Drs Grant, Weilburg, Singer, and Meigs), Boston.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Family practice patients' adherence to statin medications
Natarajan et al.
cfp 2007;53:2144-2145.
ABSTRACT | FULL TEXT  

Physician Follow-up and Provider Continuity Are Associated With Long-term Medication Adherence: A Study of the Dynamics of Statin Use
Brookhart et al.
Arch Intern Med 2007;167:847-852.
ABSTRACT | FULL TEXT  

Statin use in American Indians and Alaska Natives with coronary artery disease.
Cooke et al.
Am J Health Syst Pharm 2006;63:1717-1722.
ABSTRACT | FULL TEXT